Neonatal Drug Therapy Manual


Disclaimer: Official controlled document is the CHEO and Ottawa Hospital online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Tazidime, Fortaz
Cephalosporin Antibiotic
Original Date: 
March 1993
Revised Date: 
April 2017
  • Severe infections due to Gram (-) organisms, including Pseudomonas
  • IV direct: over 3 - 5 minutes
  • IV intermittent infusion: over 15 - 30 minutes

< 1.2 kg: 0 - 4 weeks: 100 mg/kg/day divided Q12H

1.2 - 2 kg:

  • 0 - 7 days: 100 mg/kg/day divided Q12H
  • > 7 days: 150 mg/kg/day divided Q8H

> 2 kg: 150 mg/kg/day divided Q8H

Side Effects: 
  • GI: diarrhea, vomiting, pseudomembranous colitis
  • Hematologic: eosinophilia, thrombocytosis, transient leukopenia, neutropenia, thrombocytopenia, lymphocytosis, positive Coombs test
  • Hepatic: transient elevation of liver enzymes
  • Local: phlebitis/inflammation at injection site
  • Renal: transient increase in serum creatinine and urea
Parameters to Monitor: 
  • Serum creatinine and urea
  • CBC
  • Injection site
Reconstitution and Stability: 


  • Ceftazidime 1 g vial (doses < 200 mg)
    • Add 9.4 mL SWFI to vial
    • Take 4 mL (400 mg) and add to 16 mL D5W
    • Final concentration: 20 mg/mL
  • Ceftazidime 1 g vial (doses > 200 mg)
    • Add 9.4 mL SWFI to vial
    • Final concentration: 100 mg/mL


  • Ceftazidime 1 g vial
    • Add 9.4 mL SWFI to vial

    • Take 4 mL (400 mg) and add to 16 mL D5W

    • Final concentration: 20 mg/mL


- Solutions Compatible: D5W, D10W, 0.9% NaCl, dextrose-saline combinations

- Y-site Compatible: acyclovir, dopamine, epinephrine, famotidine, furosemide, gentamicin, heparin, hydromorphone, insulin, ketamine, milrinone, morphine, ranitidine, tobramycin, TPN

Incompatible: amiodarone,  caspofungin, dobutamine, erythromycin lactobionate, fluconazole, midazolam, pantoprazole, SMOF, vancomycin


Contains 2.3 mmol of sodium per gram of ceftazidime


- Taketomo CK, Hodding JH, Kraus DM. Pediatric Dosage Handbook 22nd Edition. Hudson: Lexi-Comp Inc; 2015

- American Society on Health-System Pharmacists (ASHP). Handbook on Injectable Drugs. 19th Edition. Bethesda: ASHP 2017

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.